关键比较：扩散制药（纳斯达克股票代码：DFFN）和Forte Biosciences（纳斯达克股票代码：FBRX）

Diffusion Pharmaceuticals (NASDAQ:DFFN – Get Rating) and Forte Biosciences (NASDAQ:FBRX – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends.

Earnings & Valuation

This table compares Diffusion Pharmaceuticals and Forte Biosciences' top-line revenue, earnings per share and valuation.

Forte Biosciences is trading at a lower price-to-earnings ratio than Diffusion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

9.2% of Diffusion Pharmaceuticals shares are held by institutional investors. Comparatively, 45.7% of Forte Biosciences shares are held by institutional investors. 2.0% of Diffusion Pharmaceuticals shares are held by company insiders. Comparatively, 10.5% of Forte Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Diffusion Pharmaceuticals and Forte Biosciences' net margins, return on equity and return on assets.

Risk & Volatility

Diffusion Pharmaceuticals has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Diffusion Pharmaceuticals and Forte Biosciences, as provided by MarketBeat.

Diffusion Pharmaceuticals currently has a consensus price target of $9.50, indicating a potential upside of 58.33%. Given Diffusion Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Diffusion Pharmaceuticals is more favorable than Forte Biosciences.

Summary

Forte Biosciences beats Diffusion Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About Diffusion Pharmaceuticals

(Get Rating)

Diffusion Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen. The firm's product candidate, Trans Sodium Crocetinate, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.

About Forte Biosciences

(Get Rating)

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The firm's lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner in 2017 and is headquartered in Dallas, TX.

Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.